blog | Evommune

Skip to content

Login

Login

Subscribe to our Newsletter

Go Back to Home

Go Back to Blog

IPOs, NYSE, Evommune

Evommune Brings Chronic Inflammation Therapies to Wall Street With IPO

$Picture of {{ content.blog_author.display_name }}$ Eric Friedman

Oct 22, 2025 1:30:57 PM

Subscribe to our Newsletter

Email

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.